The lancet oncology
-
The lancet oncology · Aug 2012
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
The development of new drugs for patients with refractory urothelial cancer is still an unmet medical need. Preclinical evidence lends support to a rationale for targeting of the VEGF or platelet-derived growth-factor axis. We therefore investigated the activity and safety of pazopanib, a multitarget drug with antiangiogenic activity, in patients with urothelial cancer. ⋯ Fondazione IRCCS Istituto Nazionale dei Tumori provided the grant. GlaxoSmithKline provided the study drug and provided funding for the independent radiological review.
-
The lancet oncology · Aug 2012
Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.
Cancer is set to become a major cause of morbidity and mortality in the coming decades in every region of the world. We aimed to assess the changing patterns of cancer according to varying levels of human development. ⋯ None.